Cancer immunotherapy: Overview of immune checkpoint inhibitors

Faisal Fa'ak, Adi Diab

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Cancer treatment has been fully transformed with the development of cancer immunotherapies. The progress in the understanding of the immune system has led to the development of monoclonal antibodies targeted against regulatory immune checkpoints, which control T-cell activation. These therapies produce an antitumor response characterized by constant surveillance, specificity against tumor antigen, and long-lasting memory to protect against tumor relapse. In this chapter, we will discuss seven Food and Drug Administration-approved immune checkpoint inhibitors for the treatment of various malignancies, targeting two main signaling pathways, cytotoxic T-lymphocyte antigen 4 and programmed cell death 1/programmed cell death ligand-1.

Original languageEnglish
Title of host publicationRheumatic Diseases and Syndromes Induced by Cancer Immunotherapy
Subtitle of host publicationA Handbook for Diagnosis and Management
PublisherSpringer International Publishing
Number of pages17
ISBN (Electronic)9783030568245
ISBN (Print)9783030568238
StatePublished - Feb 16 2021


  • Anti-CTLA4 inhibitors
  • Anti-PD-1 inhibitors
  • Anti-PD-L1 inhibitors
  • Cancer immunotherapy
  • Immune checkpoint inhibitors


Dive into the research topics of 'Cancer immunotherapy: Overview of immune checkpoint inhibitors'. Together they form a unique fingerprint.

Cite this